VRDN - Quick Take - Aloha Lumvoa: FDA Approval & Pieces in Place Welcome VRDN's First Commercial Asset to the Thyroid Eye Market

Research evidence excerpt

VRDN - Quick Take - Aloha Lumvoa: FDA Approval & Pieces in Place Welcome VRDN's First Commercial Asset to the Thyroid Eye Market

duration. The label is built on the robust pivotal THRIVE and THRIVE-2 clinical trials,

5 Page Document and underscores a differentiated clinical profile, with a rapid and durable treatment effect,

including stat. sig. proptosis improvement, and Lumvoa standing as the first approved

Reasons for this report TED product to also demonstrate a sig. improvement in both diplopia response (called out in Clinical Studies on the label) and complete resolution of diplopia in active and

chronic disease. On the commercial front, mgmt notes the team is fully prepared to receive ✓ Quick Reaction to Newsflow/Volatility

patient enrollments immediately, with launch supported by ViridianCares, a comprehensive

patient support program providing tailored patient access assistance, benefit verification,

and financial support. Net, we view the breadth of the label and depth of the supporting data

as a meaningful differentiator into a competitive setup, and a strong foundation from which

VRDN can drive uptake across the full spectrum of TED patients.

We had seen concrete signs the commercial machine was nearing reality, and the

approval brings VRDN's trademark filings and intended launch brand fully to life.

Digging in pre-decision, we had identified a "LUMVOA / veligrotug" trademark alongside

what appeared to be a patient welcome kit, www.lumvoawelcomekit.com, a domain secured

just recently on May 21, 2026, offering an opt-in "to support your treatment journey with

Lumvoa, you're in control", which to us was a forward hint that there was commercial light

from the FDA interactions. That groundwork, in addition to mgmt's previous mentions of an